Novo Ozempic 2 mg MACE Analysis Shows 6% Lower Cardiovascular Risk Versus Switching to Mounjaro at EASD 2026

Ozempic 2 mg MACE findings are in the spotlight after Novo announced new retrospective real-world evidence on 29 September 2026 for adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the analysis, adults who escalated to semaglutide injection 2 mg were associated with a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) than those who switched to tirzepatide up to 15 mg. The results were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy.

The announcement was issued from Plainsboro, New Jersey, and Bagsværd, Denmark, by Novo. MACE in the analysis includes all-cause death, myocardial infarction (heart attack) and stroke. The company reported an adjusted hazard ratio of 1.06 (95% confidence interval 1.04–1.08; P=0.005) for the comparison between adults who escalated to Ozempic® (semaglutide) 2 mg and those who switched to Mounjaro® (tirzepatide). It describes the work as part of its COMPETE SWITCH CV study, which draws on claims data for 636,525 adults living with type 2 diabetes.

Michael Radin, MD, executive medical director at Novo Nordisk, said switching therapies or adjusting dosages is often necessary to reach glycemic control, yet cardiovascular risk should remain an important consideration. He noted that the data may help healthcare professionals facing a critical question: whether to increase the dose or move to another therapy for an adult with type 2 diabetes already treated with semaglutide. For clinicians weighing the Ozempic 2 mg MACE evidence, the company positions it as insight into how intensification strategies may affect cardiovascular outcomes.

Ozempic 2 mg MACE Findings Presented at EASD 2026 in Milan

Three headline points define the announcement from EASD 2026. Adults with type 2 diabetes on semaglutide injection 1 mg whose dose was increased to 2 mg were associated with a 6% lower MACE risk than those who switched to tirzepatide (up to 15 mg). The retrospective analysis covered claims data for 636,525 adults. According to Novo, the COMPETE SWITCH CV results provide insight into GLP-1 receptor agonist (GLP-1 RA) treatment adjustment in adults with type 2 diabetes.

Learn More

Novo Nordisk Ziltivekimab ZEUS Trial: Phase 3 Cardiovascular Readout Misses Primary MACE Reduction Target

A subset of the cohort included patients with type 2 diabetes and more than one HbA1c and/or weight measurement at baseline. That subset demonstrated consistent results, with an adjusted hazard ratio of 1.07 (95% confidence interval 1.01–1.13; P<0.035). Novo Nordisk said these findings build on an earlier analysis of the same data that examined HbA1c and weight loss, presented as a poster at the American Diabetes Association Scientific Sessions held 5–8 June 2026 in New Orleans. The latest Ozempic 2 mg MACE readout therefore adds a cardiovascular endpoint to that earlier glycemic and weight work.

Kathryn S. Tierney, MSN, APRN, FNP-BC, FAANP, of Middlesex Health MultiSpecialty Group in Middletown, CT, called treatment intensification a common challenge in clinical practice. She said it is especially hard for adults who have not yet met treatment goals but tolerate their current regimen well. In her view, the real-world findings suggest that escalating to semaglutide 2 mg may be a meaningful option for appropriate patients. She added that the analysis reinforces weighing cardiovascular outcomes alongside glycemic management when making treatment decisions.

How the Ozempic 2 mg MACE Analysis Was Designed

COMPETE SWITCH is a retrospective cohort study that uses Komodo Health’s Healthcare Map with linked laboratory results, a large US healthcare claims database covering January 2018 to September 2025. The study evaluated real-world treatment patterns among adults with type 2 diabetes receiving semaglutide 1 mg. It specifically compared outcomes after dose escalation to semaglutide 2 mg with outcomes after switching to tirzepatide. Novo says the collective COMPETE SWITCH analyses offer real-world insight into cardiometabolic outcomes associated with treatment strategies and decisions.

The cardiovascular component assessed MACE using an intention-to-treat approach. It included 185,705 adults who escalated to semaglutide 2 mg and 23,104 adults who switched to tirzepatide, all followed from the point of dose escalation or switching, or until the end of the study period. This structure means the Ozempic 2 mg MACE comparison rests on far more escalators than switchers, a size difference worth noting when reading the results.

Novo Nordisk defined the index date as the date of the first prescription fill for semaglutide 1 mg. Within 365 days after that date, 67.2% of the 636,525 adults remained on semaglutide 1 mg, 29.2% had escalated to semaglutide 2 mg and 3.6% had switched to tirzepatide. The company also noted that treatment effects may vary across individuals, including low or high responders. It said this heterogeneity may have significant impact on studies of dose titration and multiple sequential dosing.

Learn More

Novo – Anthropic Claude Science Partnership Targets Faster Drug Discovery

Ozempic 2 mg MACE Results: Dose Escalation and Switching Patterns

At the 720-day follow-up, fewer patients remained on semaglutide 1 mg, at 57.4%, reflecting continued treatment intensification over time. By then 36.9% had escalated to semaglutide 2 mg and 5.7% had switched to tirzepatide. These proportions show that dose escalation was the far more common intensification route in this claims-based cohort. That provides the backdrop for the Ozempic 2 mg MACE comparison.

Adults who switched began on an initial tirzepatide dose of either 2.5 mg or 5 mg, and clinicians had flexibility to titrate across the tirzepatide dosing regimen. Approximately 31% of patients who switched to tirzepatide reached a dose of 10 mg or higher during follow-up. The announcement did not report event counts, absolute event rates or dose-specific hazard ratios for the tirzepatide group. The Ozempic 2 mg MACE result should therefore be read as a single adjusted comparison rather than a dose-response analysis.

Ozempic 2 mg MACE Limitations, Safety Information and Clinical Context

Novo stated that real-world evidence can show how treatments work outside controlled clinical trial settings, but such analyses have several limitations. Results may reflect residual unmeasured confounding, and while associations can be demonstrated, causal relationships cannot be definitively established. Retrospective claims data may also exclude patients with intermittent coverage or underserved populations, potentially limiting generalizability. The company cites a peer-reviewed primer on real-world evidence for this context. Safety outcomes were not assessed, so the Ozempic 2 mg MACE data do not address tolerability.

Novo noted that semaglutide injection carries a Boxed Warning for possible thyroid tumors, including cancer. It should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, vomiting, diarrhea, stomach (abdominal) pain and constipation. Anyone considering a change in dose or therapy should discuss the Ozempic 2 mg MACE evidence and the product’s safety information with a qualified healthcare professional.

Novo describes itself as a global healthcare company with over 67,000 employees worldwide. It reports a 40-year presence in the United States, where it is headquartered in New Jersey and employs approximately 10,000 people.

DATA TABLES

Table 1: Announcement Facts

Table 2: Statistical Results Reported

Table 3: Treatment Patterns After Semaglutide 1 mg Index Date

Table 4: Cohort Sizes and Data Transparency